A review of predictive, prognostic and diagnostic biomarkers for non-small-cell lung cancer: towards personalised and targeted cancer therapy

被引:4
|
作者
Osei, Ernest [1 ,2 ,3 ,4 ]
Lumini, Julia [5 ]
Gunasekara, Dinindu [2 ]
Osei, Beverley [6 ]
Asare, Akua [7 ]
Laflamme, Raymond [8 ]
机构
[1] Grand River Reg Canc Ctr, Dept Med Phys, Kitchener, ON, Canada
[2] Univ Waterloo, Dept Phys & Astron, Waterloo, ON, Canada
[3] Univ Waterloo, Dept Syst Design Engn, Waterloo, ON, Canada
[4] Univ Guelph, Dept Clin Studies, Ontario Vet Coll, Guelph, ON, Canada
[5] Univ Waterloo, Dept Biol, Waterloo, ON, Canada
[6] McMaster Univ, Dept Hlth Sci, Hamilton, ON, Canada
[7] Brock Univ, Dept Gen Sci, St Catharines, ON, Canada
[8] Univ Waterloo, Inst Quantum Comp, Waterloo, ON, Canada
关键词
cancer therapy; chromosome aberration; genes biomarkers; non-small-cell lung cancer; protein biomarkers; CLINICALLY SELECTED PATIENTS; ANAPLASTIC LYMPHOMA KINASE; PI3K PATHWAY; OPEN-LABEL; RESISTANCE MUTATION; ACQUIRED-RESISTANCE; GEFITINIB TREATMENT; MEK INHIBITORS; EARLY-STAGE; PHASE-III;
D O I
10.1017/S1460396919000876
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Introduction: Lung cancer has a high mortality rate mainly due to the lack of early detection or outward signs and symptoms, thereby often progressing to advanced stages (e.g., stage IV) before it is diagnosed. However, if lung cancers can be diagnosed at an early stage and also if clinicians can prospectively identify patients likely to respond to specific treatments, then there is a very high potential to increase patients' survival. In recent years, several investigations have been conducted to identify cancer biomarkers for lung cancer risk assessment, early detection and diagnosis, the likelihood of identifying the group of patients who will benefit from a particular treatment and monitoring patient response to treatment. Materials and Methods: This paper reports on the review of 19 current clinical and emerging biomarkers used in risk assessment, screening for early detection and diagnosis and monitoring the response of treatment of non-small-cell lung cancers. Conclusion: The future holds promise for personalised and targeted medicine from prevention, diagnosis to treatment, which take into account individual patient's variability, though it depends on the development of effective biomarkers interrogating the key aberrant pathways and potentially targetable with molecular targeted or immunologic therapies. Lung cancer biomarkers have the potential to guide clinical decision-making since they can potentially detect the disease early, measure the risk of developing the disease and the risk of progression, provide accurate information of patient response to a specific treatment and are capable of informing clinicians about the likely outcome of a cancer diagnosis independent of the treatment received. Moreover, lung cancer biomarkers are increasingly linked to specific molecular pathway deregulations and/or cancer pathogenesis and can be used to justify the application of certain therapeutic or interventional strategies.
引用
收藏
页码:370 / 384
页数:15
相关论文
共 50 条
  • [31] Targeted therapy for non-small-cell lung cancer: past, present and future
    Forde, Patrick M.
    Ettinger, David S.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (06) : 745 - 758
  • [32] The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
    Min Yuan
    Li-Li Huang
    Jian-Hua Chen
    Jie Wu
    Qing Xu
    Signal Transduction and Targeted Therapy, 4
  • [33] Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
    Stinchcombe, Thomas E.
    Ramalingam, Suresh S.
    LANCET ONCOLOGY, 2010, 11 (06): : 500 - 501
  • [34] Correction: Targeted therapy in non-small-cell lung cancer—is it becoming a reality?
    F. Janku
    D. J. Stewart
    R. Kurzrock
    Nature Reviews Clinical Oncology, 2011, 8 : 384 - 384
  • [35] Targeted therapy in non-small-cell lung cancer-is it becoming a reality?
    Janku, Filip
    Stewart, David J.
    Kurzrock, Razelle
    NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (07) : 401 - 414
  • [36] The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
    Yuan, Min
    Huang, Li-Li
    Chen, Jian-Hua
    Wu, Jie
    Xu, Qing
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2019, 4 (1)
  • [37] Predictive value of blood biomarkers in elderly patients with non-small-cell lung cancer
    Guo, Lianghua
    Song, Bin
    Xiao, Jianhong
    Lin, Hui
    Chen, Junhua
    Jian, Baoren
    BIOMARKERS IN MEDICINE, 2023, 17 (24) : 1011 - 1019
  • [38] Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer
    Prelaj, Arsela
    Tay, Rebecca
    Ferrara, Roberto
    Chaput, Nathalie
    Besse, Benjamin
    Califano, Raffaele
    EUROPEAN JOURNAL OF CANCER, 2019, 106 : 144 - 159
  • [39] Influence of polymorphisms on EGFR targeted therapy in non-small-cell lung cancer
    Giovannetti, Elisa
    Erdem, Lale
    Olcay, Efnan
    Leon, Leticia G.
    Peters, Godefridus J.
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2011, 16 : 116 - 130
  • [40] Predictive genetic biomarkers in immune checkpoint inhibitors for non-small-cell lung cancer
    Henriques, Geane Tomaides
    de Souza, Cleide Barbieri
    Aguiar, Pedro Nazareth, Jr.
    IMMUNOTHERAPY, 2022, 14 (04) : 249 - 257